Physiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type 2 diabetes and related comorbidities (NASH, CKD and CVD), will be presenting at the 19th World Congress of Insulin Resistance, Diabetes & Cardiovascular Disease in Los Angeles, CA, Dec. 2-4 2021.
Physiogenex to present its obese NASH hamster model for severe COVID-19 at the 19th WCIRDC in Los Angeles, CA
Dr. François Briand, Director of Research and Business Development, will be presenting an abstract entitled “Diet-induced obesity and NASH aggravate SARS-CoV-2 infection in golden Syrian hamsters”.
The abstract will be presented during the poster session to be held on December the 2nd, 6:30pm-7:30pm, and during the abstract oral presentation session to be held on December the 3rd, 7:30pm-9pm.
If you wish to set an appointment with Dr. François Briand to discuss about your preclinical project, please contact us.
About the 19th WCIRDC
please visit meeting website
Physiogenex is a leading preclinical research organization providing non-clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.